Chief Medical Officer

Company Overview

SJP Biotec GmbH is a clinical-stage precision oncology company dedicated to pioneering innovative solutions in the fight against refractory cancers. Founded in 2024, SJP focuses on targeting RAS-driven, hormone-receptor-positive, and immune-refractory tumors through a cutting-edge Selective Translation Regulatory Inhibitor (STRI) platform. Our unique pipeline of small molecules is being developed in-house and is prepared to enter regulatory-grade trials.

With guidance from a highly esteemed Scientific Advisory Board of experts in RAS and breast cancer biology as well as immuno-oncology, SJP has created clinical partnerships with leading medical institutions globally including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill.

Opportunity Overview

This role presents an exciting chance to be part of a scientifically advanced and resource-efficient biotech company at a critical stage of growth. The position will involve serving as a senior clinical leader, tasked with the design and implementation of a multi-indication clinical development strategy focusing on RAS/eIF4A/translation-pathway inhibition.

Key Responsibilities

• Translate and deliver key directives from the board and senior management, representing the clinical perspective of the company.
• Lead and manage all clinical development activities within the SJP portfolio.
• Design Phase 2 and 3 clinical protocols and oversee CTA/IND submissions to BfArM, FDA, and EMA.
• Develop and implement biomarker-driven patient selection strategies.
• Build and maintain relationships with leading academic and clinical sites across Germany, the EU, and the US.
• Oversee Investigator Initiated Trials and partnerships, providing necessary scientific leadership.
• Lead regulatory strategy, developing approaches for Fast Track Designation, Breakthrough Therapy Designation, and accelerated approval pathways.
• Support pharmaceutical partnering activities, preparing clinical data packages and responding to due diligence inquiries.
• Build and expand the clinical development and operations team, including recruitment of CRAs, medical monitors, and data management staff.
• Present clinical data at major oncology congresses and to key opinion leaders.
• Engage with potential investors and financial institutions to secure necessary capital.

Candidate Profile

Essential Qualifications

• MD with a specialization in medical oncology and hematology.
• 10+ years of experience in oncology clinical development within pharma, biotech, or CRO environments with substantial clinical trial leadership experience.
• Proven track record of successful IND/CTA submissions.
• Leadership experience in interactions with regulatory bodies such as the FDA and/or EMA.
• Experience in biomarker-driven trial design and companion diagnostics development.
• In-depth knowledge of breast cancer, NSCLC, and KRAS-mutant tumor biology.
• Strong comprehension of the competitive landscape in clinical oncology treatments.
• Proven capability in managing investigator-initiated trials and academic partnerships.
• Established record of scientific publications and/or presentations at oncology congresses.
• Exceptional presentation skills.
• Ability to emphasize teamwork and lead a team of field experts.

Highly Desired Qualifications (But Not Required)

• Experience with RAS/KRAS biology, MAPK pathway inhibitors, or translation-pathway therapeutics.
• PhD in a relevant area of cancer biology.
• Experience in basket trial design and multi-cohort oncology studies.
• Background in immuno-oncology combinations, especially relating to checkpoint inhibitor resistance settings.
• Prior involvement in pharma partnering or licensing due diligence from a biotech perspective.
• Working knowledge of German regulatory frameworks alongside international GCP/ICH guidelines.
• Established professional network within leading cancer centers.